Page last updated: 2024-10-31

neostigmine and Charcot-Marie-Tooth Disease

neostigmine has been researched along with Charcot-Marie-Tooth Disease in 1 studies

Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.
neostigmine : A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.

Charcot-Marie-Tooth Disease: A hereditary motor and sensory neuropathy transmitted most often as an autosomal dominant trait and characterized by progressive distal wasting and loss of reflexes in the muscles of the legs (and occasionally involving the arms). Onset is usually in the second to fourth decade of life. This condition has been divided into two subtypes, hereditary motor and sensory neuropathy (HMSN) types I and II. HMSN I is associated with abnormal nerve conduction velocities and nerve hypertrophy, features not seen in HMSN II. (Adams et al., Principles of Neurology, 6th ed, p1343)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lobzin, VS1
Saĭkova, LA1
Shiman, AG1
Kosachev, VD1

Other Studies

1 other study available for neostigmine and Charcot-Marie-Tooth Disease

ArticleYear
[Treatment of patients with Charcot-Marie-Tooth neural amyotrophy].
    Vrachebnoe delo, 1988, Issue:12

    Topics: Adolescent; Adult; Charcot-Marie-Tooth Disease; Chronic Disease; Drug Evaluation; Drug Therapy, Comb

1988
chemdatabank.com